GRANISETRON HYDROCHLORIDE by Novartis is 5-hydroxytryptamine 3 (5-ht 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-ht 1 ; 5-ht 1a ; 5-ht 1b/c ; 5-ht 2 ; for alpha 1 -, alpha 2 - or beta-adrenoreceptors; for dopamine-d 2 ; or for histamine-h 1 ; benzodiazepine; picrotoxin or opioid receptors. First approved in 2008.
Drug data last refreshed 18h ago
5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1 ; 5-HT 1A ; 5-HT 1B/C ; 5-HT 2 ; for alpha 1 -, alpha 2 - or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1 ; benzodiazepine; picrotoxin or opioid receptors.…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on GRANISETRON HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.